Breast carcinoma

This early-stage study tests whether a DNA vaccine that targets a protein called mammaglobin-A (found on many breast cancer cells) is safe for people with ER+, HER2- breast cancer. The vaccine is given alongside standard hormone therapy or chemotherapy before surgery. The study i…

This early-stage trial tests a DNA vaccine called STEMVAC in 42 people with advanced HER2-negative breast cancer whose disease is stable or gone after standard treatment. The vaccine is designed to help the immune system recognize and attack cancer stem cells, which are often res…

This study offers continued access to the targeted cancer drug ribociclib for people with metastatic breast cancer who are already benefiting from it in a previous Novartis trial. About 134 participants will keep taking ribociclib, sometimes with other hormone therapies, while re…

This study tests whether adding a radioactive drug (radium-223) to standard chemotherapy (paclitaxel) helps people with advanced breast cancer that has spread to the bones. The radioactive drug targets bone tumors directly, while chemo works throughout the body. About 70 particip…

This early-phase study tests a new drug called OP-1250 (palazestrant) combined with other targeted therapies in people with advanced or metastatic ER-positive, HER2-negative breast cancer. The main goals are to find safe doses and check for side effects. About 190 adults will joi…

This Phase III trial tests whether giving radiation in three smaller doses (FSRS) works better than a single large dose (SRS) for cancer that has spread to the brain. About 269 adults with lung, breast, melanoma, kidney, or gastrointestinal cancers will be randomly assigned to on…

This study tests a shorter, more focused radiation treatment (hypofractionated partial breast irradiation) for women with early-stage breast cancer. The goal is to see if targeting only the tumor site can reduce side effects and improve cosmetic outcomes compared to standard whol…

This early-stage trial tests a new approach for people with a specific type of advanced breast cancer (ER+/HER2-) that has stopped responding to hormone therapy. It combines a radioactive drug (lutetium NeoB) that targets cancer cells with a standard chemotherapy pill (capecitabi…

This phase 2 trial tests three drug combinations—fulvestrant alone, fulvestrant plus palbociclib, and fulvestrant plus palbociclib plus avelumab—in 220 people with ER+/HER2- metastatic breast cancer that has progressed after prior CDK inhibitor therapy. The goal is to see which c…

This early-phase trial tests a combination of two drugs, cyclophosphamide and veliparib, in people with HER2-negative breast cancer that has spread or cannot be surgically removed. The main goal is to find the safest dose and check for side effects. Up to 35 participants will rec…

This early-phase trial tests a two-step treatment for advanced breast cancer that cannot be cured with surgery or radiation. First, patients receive a drug called talazoparib alone, then both talazoparib and avelumab together. The main goal is to check safety and side effects, wh…

This study tests a drug called disitamab vedotin in 100 adults with advanced breast cancer that has spread and is hard to treat. Participants must have tumors with HER2 protein and have had prior treatment. They receive the drug into a vein every two weeks. Researchers will check…

This early-phase trial is testing whether adding a drug called copanlisib to the standard two-drug therapy (fulvestrant and abemaciclib) can better control hormone receptor-positive, HER2-negative metastatic breast cancer that has stopped responding to hormone therapy. The study …

This large phase 3 trial studied over 10,000 women with early-stage, hormone-receptor-positive breast cancer that hasn't spread to lymph nodes. It used the Oncotype DX test to assign women to hormone therapy alone or hormone therapy plus chemotherapy based on their recurrence sco…

This early-phase trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a drug that may block cancer cell repair)—in people with advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the sa…

This early-phase study tests the safety and best dose of a drug called veliparib when given with two chemotherapy drugs (carboplatin and paclitaxel) in people with advanced solid tumors that have spread or can't be removed. It includes patients who also have liver or kidney probl…

This early-phase trial tests two different drug combinations—olaparib plus vistusertib, or olaparib plus capivasertib—in people with recurrent endometrial, triple-negative breast, ovarian, primary peritoneal, or fallopian tube cancer. The main goal is to find the safest dose and …

This study tests a system called CONCURxP that uses a smart pill dispenser (WiseBag) and text message reminders to help people with metastatic breast cancer take their CDK4/6 inhibitor pills as prescribed. About 410 patients will be split into two groups: one gets the full system…

This study tests whether precisely targeted radiation (SBRT) can treat a few growing cancer spots in patients with metastatic breast cancer, allowing them to stay on their current systemic therapy instead of switching to a new drug. Researchers will also look at whether circulati…

This early-phase trial is testing a gel form of the drug endoxifen, applied to the skin, in 32 women scheduled for breast surgery. The goal is to see if the gel is safe and how much of the drug gets into breast tissue and blood. If successful, it might offer a gentler way to trea…

This phase III trial tests whether adding pembrolizumab (Keytruda) after standard chemotherapy can help prevent triple-negative breast cancer from coming back. Over 1,100 patients with residual cancer after chemo are randomly assigned to receive pembrolizumab or placebo. The stud…

This study tests whether adding belzutifan to fulvestrant can slow or stop the growth of a certain type of advanced breast cancer (ER+/HER2-) that has worsened despite hormone therapy. About 120 adults with inoperable or metastatic disease will receive either the new combination …

This phase II trial tests whether adding an immunotherapy drug (atezolizumab) to a targeted therapy (olaparib) works better than olaparib alone for advanced non-HER2-positive breast cancer that has a BRCA mutation. About 81 patients with locally advanced or metastatic disease are…

This large phase 3 trial studied over 5,000 women with hormone receptor-positive, HER2-negative breast cancer that had spread to 1-3 lymph nodes. Participants received standard hormone therapy (tamoxifen or an aromatase inhibitor) either alone or with chemotherapy. The goal was t…

This early-phase trial tests a radioactive drug called tin-117m-DTPA in 24 people with prostate, breast, or lung cancer that has spread to the bones. The drug is designed to deliver low-level radiation directly to bone tumors while being gentler on the bone marrow. Researchers wi…

This study tests whether a newer drug, Z-Endoxifen, works better than the standard tamoxifen for postmenopausal women with advanced ER+/HER2- breast cancer. About 81 participants will receive one of the two hormone therapies to see which delays cancer growth longer. The goal is t…

This early-stage trial evaluates the safety, tolerability, and how well the body absorbs utidelone in capsule form for people with advanced solid tumors, including metastatic breast cancer. The study has three parts: finding the safest dose, comparing the capsule to the injected …

This early-phase trial tested a drug called Z-endoxifen in 62 people with a type of breast cancer that has spread or come back. The goal was to find the safest dose and check for side effects. Z-endoxifen works by blocking estrogen, which some breast cancers need to grow.

This early-stage study tests two drugs, palbociclib and avelumab, together for people with a specific type of advanced breast cancer (AR+ triple negative). The main goals are to find the safest doses and see if the combination can shrink tumors. About 45 participants will take pa…

This early-phase study tests a combination of two drugs, niraparib and dostarlimab, in 18 adults with BRCA-mutated breast, pancreas, or ovary cancer that has spread or cannot be surgically removed. Niraparib blocks a DNA repair protein in cancer cells, while dostarlimab helps the…

This phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study …

This early-stage study is testing a new drug, AB801, alone or with other treatments, in about 91 people with advanced cancers (like lung, colon, or breast cancer) that have not responded to standard therapies. The main goal is to check the drug's safety and find the best dose for…

This early-phase study tests a new oral drug, ATV-1601, in people with advanced solid tumors or certain breast cancers that have a specific AKT1 E17K mutation. The main goals are to check safety, find the right dose, and see how the drug moves through the body. About 134 adults w…

This study looks at whether people with HER2-positive metastatic breast cancer who have had their cancer controlled for at least three years can safely stop their anti-HER2 therapy. About 82 participants will either stop or continue treatment to see if the cancer stays away for a…

This phase 3 trial tests whether adding entinostat to the hormone therapy exemestane helps control advanced hormone receptor-positive breast cancer better than exemestane alone. About 600 patients with locally advanced or metastatic breast cancer are participating. The study meas…

This study tests a drug called trastuzumab deruxtecan (T-DXd) combined with other anti-cancer medicines in people with metastatic HER2-low breast cancer. The goal is to find safe doses and see if the combination can shrink tumors or slow the cancer's growth. About 138 adults with…

This early-stage trial tests a drug called berzosertib combined with radiation therapy for people with certain types of breast cancer that no longer respond to chemotherapy. The goal is to find the safest dose and see if the combination can shrink or stabilize tumors better than …

This early-phase trial tests an experimental drug called BAY 1895344 combined with standard chemotherapy (cisplatin, with or without gemcitabine) in people with advanced solid tumors, especially urothelial cancer. The goal is to find the best dose and see how safe the combination…

This study tests whether platinum-based chemotherapy (cisplatin or carboplatin) works better than capecitabine in people with a certain type of triple-negative breast cancer that remains after initial chemotherapy and surgery. About 415 participants with stage II-III breast cance…

This study tests two drugs together—disitamab vedotin and tucatinib—in people with advanced breast or stomach cancers that have a protein called HER2. The goal is to see if the combination is safe and shrinks tumors. About 172 participants will take part.

This phase 3 trial tests whether a combination of the targeted drug abemaciclib plus hormone therapy works as well as standard chemotherapy for women with ER+ HER2- breast cancer that has spread to the liver, lungs, or other organs. About 180 participants will be randomly assigne…

This study tests a drug called sacituzumab govitecan (Trodelvy) in people with advanced triple-negative breast cancer that has worsened after chemotherapy. The goal is to see how well the drug shrinks tumors and to find biological markers that predict response. Participants recei…

This trial tests whether placing a small marker clip into a breast tumor without ultrasound guidance (using touch alone) is as accurate, safe, and cost-effective as using ultrasound. The study involves 50 women with palpable breast tumors who will receive neoadjuvant chemotherapy…

This study tests an experimental oral drug called PMD-026 in people with metastatic breast cancer that has spread and is no longer curable. The drug targets a protein called RSK2 found in some tumors. The trial will check safety and how well the drug works alone or with another h…

This study tests whether analyzing the genetic makeup of a patient's triple-negative breast cancer tumor can help doctors choose the most effective treatment. Patients with newly diagnosed, early-stage triple-negative breast cancer receive either standard chemotherapy or a person…

This study tests whether a new drug called RPH-051 works as well as the approved drug Perjeta when both are given with standard chemotherapy and another targeted therapy for people with HER2-positive breast cancer that has spread or cannot be removed. About 246 participants will …

This study looks at how well older patients (65 and up) with advanced or metastatic breast cancer tolerate a chemotherapy drug called Abraxane. The goal is to see what side effects occur and whether the drug can control tumor growth. Participants receive Abraxane intravenously, a…

This early-stage trial tests a new drug called OKI-219 in people with advanced solid tumors or breast cancer that have a specific PI3K gene mutation. The drug is designed to block the mutant protein and slow cancer growth. Up to 200 participants will receive OKI-219 alone or comb…

This study looks at how well oral vinorelbine, a chemotherapy pill, works in women with advanced breast cancer. It includes women who have already taken the drug or are starting it now. Researchers track how long the cancer stays under control and how patients feel during treatme…

This phase 2 trial tests whether a vaccine made from a protein found on many triple-negative breast cancer cells can help prevent the cancer from coming back. Participants receive the vaccine along with an immune booster and a low dose of chemotherapy. The study includes women wi…

This study tests whether adding the drug tucatinib to standard therapy (trastuzumab/pertuzumab or T-DM1) can prevent new or worsening brain metastases in people with advanced HER2+ breast cancer. About 48 participants who have stable disease elsewhere but a new brain tumor will r…

This early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…

This early-stage study tests whether a mix of immune-boosting drugs and targeted radiation can help the body fight advanced solid tumors that cannot be removed by surgery. About 14 adults with certain types of skin cancer, sarcoma, or breast cancer will receive the treatment dire…

This phase III trial tests whether adding tucatinib to standard T-DM1 therapy works better than T-DM1 alone at preventing breast cancer from coming back. It involves over 1,000 patients with HER2-positive breast cancer who still have cancer cells after initial treatment. The stud…

This study tests a drug called elacestrant combined with other medicines in people with a common type of advanced breast cancer (ER+/HER2-). The goal is to find safe doses and see if these combinations can slow down cancer growth. About 435 adults with metastatic breast cancer wi…

This phase 2 trial tests whether continuing the drug palbociclib (Ibrance) while switching to a different hormone therapy, fulvestrant (Faslodex), can help control metastatic breast cancer in people whose disease has worsened on palbociclib plus an aromatase inhibitor. The study …

This phase 2 trial is testing the drug taletrectinib in people with a rare, advanced form of breast cancer called invasive lobular carcinoma that has a specific gene change (CDH1 mutation). The study aims to see if the drug can shrink tumors or slow the cancer's growth. The trial…

This phase 3 trial tests whether giving fulvestrant alone or with anastrozole before surgery works better than anastrozole alone for postmenopausal women with estrogen receptor-positive breast cancer. Over 1,400 participants will receive one of these hormone therapies for several…

This study tests a new drug, DB-1303, against standard chemotherapy in about 540 people with a specific type of advanced breast cancer (HER2-low, hormone receptor-positive) that has stopped responding to hormone therapy. The main goal is to see if DB-1303 can delay cancer growth …

This early-phase trial tests a combination of two drugs—veliparib and carboplatin—in people with HER2-negative breast cancer that has spread. The goal is to find the best dose and see if the combo is safe. Veliparib may help carboplatin work better by stopping cancer cells from r…

This phase II trial at Mayo Clinic tests whether estradiol, a form of estrogen, can help patients with a specific subtype of triple negative breast cancer that has a receptor called ER beta. The study enrolls 8 women with advanced or metastatic disease. Researchers will measure h…

This Phase 2 trial tests the drug elacestrant in 61 people with estrogen receptor-positive, HER2-negative metastatic breast cancer who have not previously used CDK4/6 inhibitors. Participants take a daily pill for about 6 months. The study aims to see if the drug can delay cancer…

This study tests whether a single, focused radiation treatment works as well as five treatments for people with low-risk stage 0 or I breast cancer after a lumpectomy. About 134 participants will be randomly assigned to receive either one or five doses of radiation to the tumor a…

This phase 3 trial tests whether adding the drug carboplatin to standard chemotherapy (doxorubicin, cyclophosphamide, and paclitaxel) helps prevent triple-negative breast cancer from coming back. About 782 patients with high-risk or node-positive disease are participating. The st…

This phase II trial is testing a type of radiation called proton beam therapy for women with early-stage breast cancer (stage 0 to II). The goal is to see if this targeted approach can kill cancer cells while causing less damage to normal tissue, leading to fewer side effects and…

This phase 2 trial tests whether combining immunotherapy (avelumab) with other drugs can shrink tumors in people with advanced triple-negative breast cancer that has spread or come back. About 145 participants will receive one of several drug combinations, including avelumab plus…

This study tests whether adding the experimental drug ipatasertib to standard hormone therapy and targeted drugs can help people with a certain type of advanced breast cancer (ER+/HER2-) live longer without their cancer growing. It includes 57 participants whose cancer did not re…

This study tests whether adding the drug panitumumab to standard chemotherapy helps shrink tumors more effectively in people with a rare and aggressive type of breast cancer called triple-negative inflammatory breast cancer. About 42 participants will receive chemotherapy before …

This study tests a combination of three drugs (nivolumab, bicalutamide, and ipilimumab) in 30 people with advanced HER2-negative breast cancer that has spread. The goal is to see if this chemo-free approach can control the disease for at least 24 weeks. Participants must have mea…

This phase II trial is testing whether giving two chemotherapy drugs, carboplatin and nab-paclitaxel, before surgery can improve outcomes for people with locally advanced or inflammatory triple negative breast cancer. The goal is to see if this approach increases the rate of comp…

This study tests whether a highly focused type of radiation called stereotactic body radiation therapy (SBRT) can delay cancer progression in women with metastatic breast cancer who are starting their first treatment. About 154 participants will receive either standard therapy al…

This early-stage trial tests the safety of combining two drugs, olaparib and vorinostat, in people with advanced breast cancer that has returned or spread. About 28 participants will receive the combination to find the best dose and check for side effects. The goal is to see if t…

This study tests a new drug (MEN1611) combined with chemotherapy (eribulin) for people with advanced breast cancer that has specific genetic changes (PIK3CA/PTEN). The goal is to see if the combination can shrink tumors or stop them from growing. About 14 participants will receiv…

This study tests a new treatment for women with metastatic breast cancer that has spread. It combines specially trained immune cells (HER2 BATs) that attack cancer cells with a drug called pembrolizumab that helps the immune system work better. The goal is to find a safe dose and…

This phase II trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard hormone therapy (letrozole or fulvestrant) and the targeted drug palbociclib can shrink tumors in postmenopausal women with newly diagnosed stage IV estrogen receptor-positive bre…

This study tests a new way for cancer doctors and primary care doctors to work together to help cancer survivors manage other health problems like high blood pressure, diabetes, and high cholesterol. About 800 adults with certain cancers and at least one of these conditions will …

This study tests whether adding the experimental drug onvansertib to standard chemotherapy (paclitaxel) can safely shrink tumors in people with triple-negative breast cancer that has spread. About 50 adults with advanced or metastatic disease will receive the combination. The goa…

This study aimed to see if the drug trastuzumab deruxtecan worked better than standard CDK4/6 inhibitors for people with a specific advanced breast cancer (ER-positive, HER2-low, non-luminal A). It was designed for adults with metastatic disease. However, the trial was withdrawn …

This phase 3 study tests a drug called sacituzumab govitecan (Trodelvy) against standard chemotherapy in 331 Asian patients with HR+/HER2- metastatic breast cancer who have already tried at least two prior chemotherapies. The goal is to see if the new drug can delay cancer growth…

This study tests an experimental drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The trial includes cancers like glioblastoma, melanoma, breast, and prostate cancer. It aims to find a safe dose and see if the drug can shrin…

This phase 2 study tests the drug abemaciclib, either alone or with tamoxifen, in 234 women with a specific type of advanced breast cancer (HR+, HER2-). The goal is to see if these treatments can slow cancer growth in patients whose disease has progressed after prior therapies. P…

This study tests a precise type of radiation called proton therapy for people with early-stage breast cancer. The goal is to see if it can control the cancer and reduce side effects compared to standard radiation. About 150 adults aged 40 and older who had a lumpectomy are taking…

This study tests whether a combination of two targeted pills (fluorizoparib and apatinib) works better than standard chemotherapy for people with a specific genetic type of advanced breast cancer (HRD-positive, HER2-negative). About 200 participants will be randomly assigned to e…

This study tests a new combination of two drugs—niraparib and trastuzumab—in people with metastatic HER2-positive breast cancer, an aggressive form of the disease. The goal is to see if the combo is safe and can shrink tumors or slow cancer growth. About 46 women with advanced ca…

This study tests whether adding pembrolizumab (Keytruda) to sacituzumab govitecan helps people with a common type of advanced breast cancer (HR+/HER2-). About 110 participants receive either the combination or sacituzumab alone. The goal is to see if the combo delays cancer growt…

This phase 2 study tests the drug olaparib in 114 people with metastatic breast cancer whose tumors have mutations in certain DNA repair genes (like BRCA1, BRCA2, ATM, PALB2, and others). Olaparib is a PARP inhibitor that may kill cancer cells by blocking their ability to fix dam…

This phase II trial tests whether combining the immunotherapy drug pembrolizumab (Keytruda) with the hormone therapy fulvestrant (Faslodex) can help control advanced or metastatic breast cancer that is hormone receptor positive and HER2 negative. The study includes 47 adults and …

This phase 3 trial tests whether giving denosumab every 12 weeks instead of every 4 weeks can still prevent bone complications (like fractures or spinal cord compression) in people with metastatic breast or prostate cancer. About 1,380 participants with bone metastases will be ra…

This study aimed to see if the drug capivasertib could clear cancer DNA from the blood of women with ER-positive breast cancer who had finished initial treatment. The goal was to prevent the cancer from coming back or spreading. However, the study was withdrawn before any partici…

This study is testing the safety and effectiveness of combining trastuzumab deruxtecan (T-DXd) with other cancer drugs for people with HER2-positive metastatic breast cancer. About 245 participants will receive different drug combinations to find the best doses and see if the tum…

This study looks at whether adding a high-precision type of radiation called SBRT to usual cancer treatments (like hormone therapy or chemo) can delay cancer growth in people with breast, lung, or prostate cancer that has spread to 1 to 5 bones. About 168 adults aged 18-75 with g…

This study tests whether adding a targeted drug called AZD5363 to the standard hormone therapy fulvestrant can slow the growth of advanced estrogen-receptor-positive (ER+) breast cancer. It involves 149 postmenopausal women whose cancer has worsened despite prior treatment with a…

This early-stage trial tests a modified herpes virus (BS006) that is injected directly into tumors to kill cancer cells and activate the immune system. It involves 29 adults with advanced solid tumors like melanoma or breast cancer. The study is currently suspended, and its main …

This study tests whether giving a short course of radiation to part of the breast before surgery is safe and practical for women with early-stage breast cancer. About 98 women over age 50 with small, hormone-sensitive tumors will receive radiation, then have surgery. Researchers …

This study tests a technique called axillary reverse mapping during breast cancer surgery. Doctors inject a radioactive tracer and blue dye to map the arm's lymph drainage, hoping to avoid damaging those vessels and reduce the risk of lymphedema (arm swelling). The study involves…

This early-stage study tests a new drug called BL-M17D1 in 120 adults with advanced solid tumors that have HER2 protein or gene changes. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Participants must have tried at least one standard…

This study tests a combination of two drugs, lenvatinib and letrozole, given before surgery to postmenopausal women with a common type of breast cancer (hormone receptor positive). The goal is to see if the drugs can shrink the tumor enough to improve surgical outcomes. About 40 …

This study tests an oral chemotherapy drug called Lonsurf in people with metastatic breast cancer that has spread. The trial includes two groups: those who have had a certain type of chemo before and those who haven't. Researchers want to see if Lonsurf can stop the cancer from g…

This study looks at whether women aged 50 and older with a specific low-risk type of early breast cancer (luminal A) can safely skip radiation therapy after surgery. About 1,167 participants are randomly assigned to receive either standard radiation plus hormone therapy or just h…

This study is testing a precise type of radiation called proton therapy for women with stage II or III breast cancer who need radiation to the whole breast or chest wall and lymph nodes. The goal is to see if this approach causes fewer side effects, especially to the heart, compa…

This study tests whether contrast-enhanced mammography (CEM) — a mammogram with an iodine dye injection — can find breast cancer more accurately than standard mammography. Researchers will compare CEM with other imaging methods in 100 women who have suspicious breast findings and…

This study is testing whether regular MRI scans of the brain can find cancer that has spread from the breast to the brain, even before symptoms appear. It involves 214 people with metastatic or inflammatory breast cancer. The goal is to see if early detection through screening im…

This early-phase trial explores whether two experimental PET/CT tracers, 68Ga-FAPI-46 and 68Ga-PSMA-11, can accurately highlight various non-prostate cancers, including breast, lung, and pancreatic tumors. Participants scheduled for surgery will receive the tracers before their s…

This study looks at whether a special type of mammogram called contrast-enhanced mammography (CEM) can more accurately predict breast cancer in women with suspicious calcium spots in the breast. About 59 women with large areas of these spots will get both a standard mammogram and…

This study tests a special type of mammogram called CESM, which uses a dye injected into a vein to make breast tissue and blood vessels clearer. The goal is to see if CESM is better than standard mammograms at finding the cause of nipple discharge and detecting breast cancer. Abo…

This study compares two types of PET scans to see which is better at finding and tracking metastatic lobular breast cancer. About 30 adults with this type of cancer will receive both an experimental FES PET/CT scan and a standard FDG PET/CT scan. The goal is to improve detection …

This phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…

This phase 2 trial tests whether a PET scan using a radioactive form of estrogen (FES) can predict how well endocrine therapy works in 99 women with newly diagnosed metastatic breast cancer. The scan lights up cancer cells that have estrogen receptors, helping doctors see if the …

This study tests whether a special type of ultrasound, using a contrast dye called Definity, can measure pressure inside breast tumors to predict how well chemotherapy is working. About 200 women with locally advanced breast cancer will get three of these ultrasounds before and d…

This phase 2 trial tests whether a new radioactive tracer called [18F]FluorThanatrace can improve PET/CT scans in 36 people with breast cancer. The tracer is designed to highlight an enzyme linked to cancer growth. Participants will receive the tracer before their standard surger…

This study tests whether checking sentinel lymph nodes during breast cancer surgery (using a rapid freezing method) helps surgeons decide right away if more lymph nodes need to be removed, compared to the usual method of waiting for final results after surgery. About 142 women wi…

This study tests a new radioactive tracer called 18F-alphavbeta6-binding-peptide to see if it can safely and clearly show cancers in the breast, colon, lung, or pancreas. About 27 adults with these cancers will get the tracer and have a PET scan. The goal is to find out if this m…

This study tested whether a special PET scan using a radioactive tracer can predict how well patients with advanced HER2-positive breast cancer respond to the drug T-DM1. Ten women with cancer that had spread to other parts of the body received the scan before treatment. The goal…

This phase 2 trial is testing whether a special PET scan using copper Cu64-DOTA-trastuzumab can predict how well HER2-positive breast cancer responds to trastuzumab and pertuzumab before surgery. The study involves 18 women with locally advanced HER2-positive breast cancer. The g…

This study tests different programs to help people at high risk for cancer (such as those with BRCA or Lynch syndrome) or cancer survivors increase their physical activity and eat healthier. The goal is to see which programs work best to reduce cancer risk. About 337 participants…

This study tests a natural substance called GM1 to see if it can prevent nerve damage (pain, numbness, tingling) caused by the chemotherapy drug paclitaxel in people with metastatic breast cancer. About 98 participants will receive either GM1 or a placebo alongside their chemo. T…

This study tests whether a lifestyle program combining aerobic exercise, strength training, and dietary coaching can reduce breast cancer risk in normal-weight postmenopausal women. The goal is to lower body fat and inflammation, which are linked to higher cancer risk even in wom…

This study tests whether moving lymph nodes from one part of the body to the armpit during breast reconstruction can lower the risk of lymphedema, a painful arm swelling. Thirty breast cancer patients who had mastectomy and lymph node removal will receive the extra procedure. Res…

This study tests whether a patient navigator—a guide who helps women understand their options—can improve how high-risk women manage their breast cancer risk. About 75 women with a family history of breast cancer but no personal diagnosis will receive support to make informed cho…

This study tests whether adding a photo guide to standard counseling helps reduce anxiety and depression in women with early-stage breast cancer who are about to start radiation therapy. About 62 participants will either receive standard verbal counseling alone or with a pictoria…

This study tests whether a remotely delivered program that combines mindfulness, physical activity tracking, and social support is acceptable and feasible for people with metastatic breast cancer. The program lasts 8-12 weeks and includes a wearable activity tracker and weekly ch…

This study tests whether a personalized support program led by a nurse can help prevent memory and thinking problems that often occur after chemotherapy in women with non-metastatic breast cancer. Fifty women will receive regular face-to-face and telephone interviews over 9 month…

This study tests whether a single oral dose of cannabidiol (CBD) can reduce the anxiety people with advanced breast cancer feel before undergoing CT or PET scans. Participants are randomly assigned to receive either CBD or a placebo, and their anxiety levels are measured before a…

This study tests whether a shorter course of higher-dose radiation (hypofractionated) is as good as or better than standard radiation for early-stage breast cancer. About 300 women with ductal carcinoma in situ or early invasive breast cancer are participating. The main goal is t…

This study tests a telemedicine program called FOCUS that helps advanced cancer patients manage common symptoms like trouble sleeping, worry, tiredness, and low mood. The program uses counseling techniques delivered through a phone app. Researchers will enroll 120 adults with adv…

This study tested a 24-week weight loss program delivered via video calls for 22 breast cancer survivors who were overweight or obese. The goal was to see if the program was practical and well-liked, and whether it improved quality of life, physical activity, and mood. Participan…

This study compares a 3-week course of radiation to the standard 5-week course for breast cancer patients who need radiation to the lymph nodes. The goal is to see if the shorter schedule is just as effective at preventing cancer from coming back, while causing less arm swelling …

This study tests a mobile lifestyle program for women with breast cancer who have unhealthy habits. The program offers coaching on diet, exercise, stress management, mindfulness, and sleep. Researchers want to see if it's practical and helps improve quality of life. About 30 wome…

This study tests whether a cream made with caffeine can help prevent skin hardening and other complications in breast cancer patients who need radiation after mastectomy with tissue expander reconstruction. About 60 participants will use either the caffeine cream or a placebo cre…

This pilot study tests whether a home-based virtual program of cardio and yoga (IM@Home) can help breast cancer patients undergoing radiation feel less fatigued and more active. Forty participants will wear a FitBit and attend online classes. The goal is to see if the program is …

This study tests whether coaching people with breast cancer on diaphragmatic breathing helps them take larger, more consistent breaths during radiation therapy. Better breath holds can protect nearby organs like the heart and lungs. The study involves 40 adults and uses lung func…

This study is testing whether a 9-month, individually tailored exercise program can reduce physical fatigue and improve quality of life in 357 people with stage IV breast cancer. Participants work with a trained instructor to follow a personalized exercise plan. The main goal is …

This phase 2 trial tests whether electroacupuncture can reduce chronic pain in women who have completed treatment for stage I-III breast cancer. 111 participants will receive either real acupuncture, sham acupuncture, or no treatment. The goal is to see if this gentle needle ther…

This study looks at two ways to give radiation to brain tumors in people who are also receiving immunotherapy for cancers like lung, breast, kidney, or melanoma. The standard approach gives one high dose of radiation, while the experimental approach gives smaller doses over sever…

This pilot study tests whether a trained Patient Support Coordinator (PSC) can help women with advanced breast cancer feel more heard and understood. Over three months, 28 participants will have regular supportive listening sessions alongside their usual medical care. The goal is…

This study tests whether eating only within a 10-hour window each day can help prevent frailty in people over 55 who are on hormone therapy for prostate cancer. Frailty makes it harder to recover from stress and can lead to loss of independence. The trial will enroll 30 participa…

This study tests whether a 6-week online program based on Acceptance and Commitment Therapy (ACT) can help cancer survivors who have finished treatment feel less anxious and depressed. 32 survivors of breast, colon, or rectal cancer will be randomly assigned to either the online …

This study tests whether an extra meeting with a team of doctors, a palliative care specialist, and a psychologist can help patients with advanced cancer feel less torn about their next treatment. 62 adults with metastatic lung, breast, colon, ovarian, or prostate cancer who need…

This study follows 25 women with advanced breast cancer to understand why the drug palbociclib stops working over time. Researchers collect blood and tumor samples before and after the cancer progresses to look for genetic and chemical changes. The goal is not to treat the diseas…

This study looks at skin and soft tissue removed during breast implant surgery after mastectomy. Researchers want to see if the physical properties of the tissue can help predict complications like implant loss. The goal is to better understand risks and improve surgical outcomes…

This study aimed to evaluate how community cancer centers test for biomarkers in common solid cancers like breast, lung, and colorectal cancer. Researchers planned to survey pathology practices to see if they follow guidelines for key tests and how quickly results are reported. T…

This study tests a computer app that shows personalized images of what breast reconstruction might look like after surgery. The goal is to help patients make more informed decisions and reduce confusion. About 35 adults planning mastectomy and immediate reconstruction at MD Ander…

This phase 2 trial is testing whether a special type of PET/CT scan (FDG-PET/CT) can better measure how breast cancer that has spread to the bones responds to treatment. The study involves 138 participants with hormone receptor-positive metastatic breast cancer that is mostly in …

This study tests a web-based education tool called HOPE-Genomics that teaches cancer patients about their genetic test results. About 465 adults with breast, colorectal, lung, ovarian, pancreatic, or prostate cancer are taking part. The goal is to see if the tool helps patients r…

This study enrolls 400 adolescents and young adults (ages 18-39) recently diagnosed with various cancers. Participants are randomly assigned to either choose which health-related questions they answer or receive a fixed set of questions. The goal is to see if giving patients a ch…

This phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …

This study looks at whether certain genetic variations can predict which women with early-stage breast cancer will stop taking anastrozole, a common hormone therapy, because of joint and muscle pain. Researchers will follow about 1,046 postmenopausal women who are prescribed anas…

This study aims to map the genetic makeup of breast and prostate cancers in patients treated through Brazil's public health system. Researchers will analyze tumor and normal DNA from 882 participants to build a national database. The goal is to better understand how genetics and …

This pilot study aims to see if doctors can consistently measure paclitaxel levels in the blood of cancer patients receiving the drug. The goal is to eventually adjust doses to give enough chemo to fight cancer while reducing the common side effect of nerve damage. The study invo…

This study tracks hair loss in 170 women with breast cancer who are taking hormone therapy. Researchers want to learn how common hair loss is, when it starts, how long it lasts, and how severe it gets. Participants will fill out questionnaires about their hair loss and quality of…

This study explores whether genetic testing from a simple saliva sample can improve risk assessment for breast cancer in women who need a breast biopsy. Researchers will analyze DNA from saliva to calculate a polygenic risk score and compare it with biopsy results and medical rec…

This study explores whether a Nectin-4 PET scan can predict how well a Nectin-4-targeted therapy works in people with advanced breast cancer. Forty participants will receive both a standard PET scan and a Nectin-4 PET scan before starting treatment, and some will have a repeat sc…

This study looks back at medical records of 300 people with metastatic luminal A or luminal B breast cancer who were treated with CDK4/6 inhibitors (Palbociclib, Ribociclib, or Abemaciclib). The goal is to see how long patients lived without their cancer getting worse, and whethe…

This study looks at tumor samples from over 3,000 people with advanced cancers to find specific biomarkers—unique features of each cancer. The goal is to help doctors choose the most promising targeted therapy or clinical trial for each patient. Participants are adults with vario…

This study looks at real-world treatment patterns and outcomes for nearly 8,000 people with HER2-altered metastatic breast cancer in the United States. Researchers will analyze data from medical records to understand how patients are treated and how long they live. The goal is to…

This study tests whether a genetic counseling video delivered through a patient portal works as well as traditional in-person genetic counseling for women at elevated breast cancer risk. About 874 women aged 30-64 will be randomly assigned to either the video or standard counseli…

This study tests a special PET scan (FES) that tracks estrogen receptors in breast cancer tumors. Researchers want to see if changes in scan results before, during, and after hormone therapy can show how well the treatment is working. The study involves adults with estrogen recep…

The PRECISION trial is studying whether women with a specific type of early-stage breast cancer can safely avoid radiation therapy after having a lumpectomy. Participants have tumors that are small, hormone receptor-positive, HER2-negative, and low-grade. A gene test called Prosi…

This study looks at whether regular blood tests can detect changes in stage IV breast cancer during treatment. Researchers will collect blood samples from 150 adults with metastatic breast cancer and analyze them for tumor DNA. The goal is to see if these tests can spot when the …

This study at Johns Hopkins is testing whether genetic information from a blood sample can match what is found in a tumor biopsy for people with metastatic breast cancer. Researchers will use the results to suggest personalized treatment options. The goal is to see if a simple bl…

This study looks at genetic changes in blood and tumor samples from women with advanced hormone receptor-positive, HER2-negative breast cancer who are being treated with palbociclib and endocrine therapy. By comparing genetic material from the cancer tissue with that found in the…

This study looks at how age changes the way the body handles a breast cancer drug called nab-paclitaxel. Researchers are studying 40 people with metastatic breast cancer to see if older patients process the drug differently. The goal is to make chemotherapy safer and more effecti…

This study collects blood and tissue samples from 300 people with breast cancer that has spread or come back. The goal is to create a large research registry that helps doctors understand why tumors spread and why people respond differently to treatments. Participants provide sam…

This study looks at how the activity of an enzyme called DPD influences how well the chemotherapy drug capecitabine works in women with metastatic breast cancer. Researchers will measure DPD activity before treatment and track tumor response over 24 months. The goal is to see if …

This research study collects tissue, blood, and other samples from 2,400 people diagnosed with breast, colon, kidney, liver, multiple myeloma, or prostate cancer at a young age. The goal is to identify genetic changes that may explain why these cancers occur early, especially in …

This study is a registry that tracks side effects and outcomes in people who have undergone cryoablation (freezing) for early stage breast cancer. It is not testing a new treatment but rather collecting real-world data on symptoms, complications, and follow-up results. Only 2 par…

This study tests a program to improve follow-up care for breast cancer survivors in primary care clinics. The program includes training, expert advice, and feedback for clinic staff. Researchers will see if it helps clinics provide more complete care for managing symptoms and lon…

This study surveys women aged 18-45 diagnosed with gynecological or breast cancer to understand how they think about having children after treatment. Researchers aim to gather insights that could help future patients and survivors make informed choices about cancer treatment and …

This study tests whether watching a short video can improve understanding of tumor genomic testing in 243 adults with metastatic cancer. Participants watch the video and then answer questions to measure their knowledge. The goal is to see if this simple tool helps patients better…

This early-stage study tests a new type of marker that can be seen more clearly on ultrasound. It is placed in lymph nodes where breast cancer has spread. The goal is to see if the marker is safe, stays in place, and helps surgeons find the cancer during surgery. About 15 people …

This study tracks 65 people with metastatic breast cancer to see if a blood test that finds cancer cells (called circulating tumor cells) helps doctors choose the right treatment and check if it's working. Participants give blood samples and doctors answer surveys about how usefu…

This study takes tumor tissue from 50 women with invasive breast cancer and grows mini 3D versions called organoids in the lab. These organoids are used to collect tiny particles called extracellular vesicles, which naturally seek out tumor cells. The goal is to use these particl…

This study follows 140 breast cancer patients who were part of the original BEAUTY trial. Researchers will collect blood and tissue samples and health information over time to understand why some breast cancers respond to standard chemotherapy and others do not. The goal is to id…

This study looks at how the drug tucatinib enters and works in HER2+ cancers that have spread to the brain. Nine adults with breast, lung, or other cancers will take tucatinib before brain surgery. Researchers will test tumor samples to find genetic clues about why some cancers s…

This study is testing a tool called MammoScreen, a simple questionnaire that helps identify women at average or increased risk for breast cancer. The goal is to see if using this tool in clinics leads to more appropriate screening referrals. About 1,141 women aged 40 to 74 who us…

This study is testing commercially available antibodies to see if they can identify breast cancer markers in blood samples. Researchers will collect blood from 84 people, including breast cancer patients and healthy volunteers. The goal is to improve detection of circulating tumo…

This study follows over 96,000 Seventh-day Adventists in the U.S. and Canada to see how diet and lifestyle choices relate to breast, colorectal, and prostate cancer. Researchers are focusing on intakes of meat, soy, and dairy. Because it is observational, it can show patterns but…

This study looks at whether a blood test that tracks tumor DNA (ctDNA) can help doctors switch treatments earlier in people with metastatic breast cancer. The goal is to see if acting on a molecular signal of progression, before symptoms or scans show it, can keep the cancer unde…

This study looks at 197 women with advanced breast cancer to compare survival between those whose tumors lost estrogen receptors (ER) and those with triple-negative disease. Researchers used a special PET scan to track receptor changes. The goal is to understand how these changes…

This study looks at whether simple blood tests can tell if a woman's metastatic breast cancer is stable, so she can skip some routine scans. About 97 women with ER-positive/HER2-negative cancer will give blood samples at each scan visit. The goal is to create a smart algorithm th…

This study follows 546 women with non-metastatic breast cancer to see how chemotherapy or endocrine therapy affects their hair, skin, and nails. Researchers will use clinical exams, photos, and questionnaires to track changes and identify who is most at risk. The goal is to bette…

This study looks at why women might want to get their screening mammogram results during the same visit, instead of waiting. Researchers will survey female patients aged 30 and older at three breast imaging centers. The goal is to understand patient preferences and improve the ov…

This study was designed to see if getting an IV in the arm that had breast cancer surgery increases the risk of lymphedema (arm swelling). Researchers planned to use a special dye called indocyanine green (ICG) and a camera system (SPY angiography) to watch how fluid moves throug…

This study tracks how much time people with advanced breast or ovarian cancer spend on care-related tasks like appointments, travel, and managing symptoms. Participants use a smartphone app for 28 days to log activities and complete surveys about their well-being. The goal is to …

This study follows 500 adults aged 18-65 who completed chemotherapy for certain cancers and are in remission. Researchers will check for 19 possible late side effects over 5 years, including heart, lung, and hormone problems. The goal is to catch these issues early and connect pa…

This early-phase study tests whether a special PET scan using a tracer called FLT can show how breast cancer tumors respond to a combination of two drugs, ribociclib and paclitaxel. The study involves 20 people with metastatic breast cancer that has spread beyond the liver and bo…